{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:35:56Z","timestamp":1790127356734,"version":"4.0.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/bor.0000000000000035","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T08:14:52Z","timestamp":1390292092000},"page":"169-175","source":"Crossref","is-referenced-by-count":51,"title":["Uricosuric drugs"],"prefix":"10.1097","volume":"26","author":[{"given":"Mary H.","family":"Bach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Simkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008.","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"for the National Arthritis Data WorkgroupEstimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II.","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R3-12-20210128","first-page":"1909","article-title":"Essential hypertension, progressive renal disease and uric acid: a pathogenetic link J Am Soc N","volume":"16","author":"Johson","year":"2005","journal-title":"ephrol"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15257770802138558","article-title":"Uric acid: the oxidant-antioxidant paradox.","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2008.05.022","article-title":"Uric acid: a marker of increased cardiovascular risk.","volume":"202","author":"Gagliardi","year":"2009","journal-title":"Atherosclerosis"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11926-012-0309-8","article-title":"Genetics of hyperuricemia and gout: implications for the present and future.","volume":"15","author":"George","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrrheum.2012.144","article-title":"The genetics of hyperuricaemia and gout.","volume":"8","author":"Reginato","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cbpa.2006.01.034","article-title":"Molybdenum nad tungsten enzymes: the xanthine oxidase family.","volume":"10","author":"Brondino","year":"2006","journal-title":"Curr Opin Chem Biol"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11926-010-0093-2","article-title":"New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.","volume":"12","author":"Schlesinger","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0272-6386(98)70067-8","article-title":"Regulation of renal urate excretion: a critical review.","volume":"32","author":"Maesaka","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Care Res"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/ard.28.4.366","article-title":"Studies of uric acid pool size and turnover rate.","volume":"28","author":"Scott","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/art.1780220121","article-title":"Uric acid excretion in patients with gout.","volume":"22","author":"Simkin","year":"1979","journal-title":"Arthr Rheum"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthr Rheum"},{"key":"R16-12-20210128","first-page":"1","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia.","volume":"3","author":"Kimiyoshi","year":"2012","journal-title":"Nat Commun"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout.","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Safety"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability drugs in gout: a randomized controlled trial of benzbromarone verus probenecid after failure of allopurinol.","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamics interaction between allopurinol and probenecid in healthy subjects.","volume":"47","author":"Stocker","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels.","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs).","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol Ther"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1371\/journal.pgen.0030194","article-title":"The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.","volume":"3","author":"Li","year":"2007","journal-title":"PLoS Genet"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"e1000246","DOI":"10.1371\/journal.pgen.1000246","article-title":"Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog.","volume":"4","author":"Bannasch","year":"2008","journal-title":"PLoS Genet"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/art.1780080429","article-title":"Role of the intestinal tract in the elimination of uric acid.","volume":"8","author":"Sorensen","year":"1965","journal-title":"Arth Rheum"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1389200043489199","article-title":"The MRP-related and BCRPABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.","volume":"5","author":"Haimeur","year":"2004","journal-title":"Curr Drug Metab"},{"key":"R27-12-20210128","first-page":"5rall","article-title":"Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.","volume":"1","author":"Maatsuo","year":"2009","journal-title":"Sci Transi Med"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI42344","article-title":"Uric acid transport and diseases.","volume":"120","author":"So","year":"2011","journal-title":"J Clin Invest"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","article-title":"Renal transport of uric acid: evolving concepts and uncertainties.","volume":"19","author":"Bobulescu","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.50.9.631","article-title":"Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.","volume":"50","author":"Yamamoto","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"R31-12-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11095-006-9181-4","article-title":"Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.","volume":"24","author":"Rizwan","year":"2007","journal-title":"Pharm Res"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.","volume":"283","author":"Anzai","year":"2008","journal-title":"J Biol chem"},{"issue":"Suppl 3","key":"R33-12-20210128","first-page":"320","article-title":"RDEA594: a potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT3 abstract.","volume":"68","author":"Yeh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R34-12-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev-med-080911-105830","article-title":"New Therapies for Gout.","volume":"64","author":"Crittenden","year":"2013","journal-title":"Annu Rev Med"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease.","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 3","key":"R36-12-20210128","first-page":"187","article-title":"Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide abstract.","volume":"70","author":"Tan","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"R38-12-20210128","first-page":"104","article-title":"Efficacy and safety of lesiurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, double-blind, placebo-controlled, Phase 2B study abstract.","volume":"70","author":"Perez-Ruiz","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"R39-12-20210128","first-page":"188","article-title":"Lesinurad (RDEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100 response achieved for all combination dose regimens abstract.","volume":"70","author":"Fleischmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R40-12-20210128","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/annrheumdis-2012-eular.2846","article-title":"RDEA3170 a novel high affinity URAT1 inhibitor binds to central domain within URAT1.","volume":"71","author":"Miner","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R42-12-20210128","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using antihyperuricaemic agents with fenofibrate andor losartan on uric acid metabolism.","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:21:22Z","timestamp":1746116482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201403000-00012"}},"subtitle":["the once and future therapy for hyperuricemia?"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000035","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}